<DOC>
	<DOC>NCT00503243</DOC>
	<brief_summary>The aim of this study was to investigate the safety and efficacy of SPD476 2.4 g/day given twice daily ([BID] ie 1.2 g/day BID) and SPD476 4.8g/day given QD compared to placebo in subjects with acute, mild to moderate ulcerative colitis.</brief_summary>
	<brief_title>Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>newly diagnosed or diagnosis of relapsing (relapsed &lt;= 6 weeks to baseline) mild to moderate ulcerative colitis women not of childbearing potential or WOCP who agreed to use an effective contraceptive method severe ulcerative colitis or relapsed for &gt; 6 weeks prior to baseline subjects who had relapsed on maintenance therapy with doses of mesalazine &gt; 2.0 g/day subjects with Crohn's disease, proctitis, bleeding disorders or active peptic ulcer disease subjects with asthma if they were known to be mesalazinesensitive subjects who were at immediate or significant risk of toxic megacolon subjects who had previous resective colonic surgery subjects who had moderate or severe renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>